The future of immunotherapy

Episode Summary

Executive Summary: Stanford’s Russ Altman interviews biochemist Lingyin Li about a strategy to improve cancer immunotherapy for solid tumors by exposing them to the immune system. Li explains how tumors camouflage themselves by degrading a danger signal via ENPP1, and how her lab developed inhibitors to block that masking mechanism, boost T-cell attack, and produce striking mouse results across aggressive cancers.

Main Topics: Why solid tumors resist immunotherapy (Priority: 5/5): The episode contrasts blood cancers, where circulating T cells can more easily attack, with solid tumors that exclude immune cells and evade detection. Immune system basics and T-cell killing (Priority: 5/5): Li explains the division between innate and adaptive immunity, how innate cells detect abnormal signals, and how T cells directly kill matched cancer cells. Cancer camouflage via DNA danger signaling (Priority: 5/5): Tumors leak DNA, triggering an innate danger signal that recruits immune cells; cancers counter this by producing ENPP1 to destroy that signal and remain hidden. ENPP1 as a therapeutic target (Priority: 5/5): Li’s group developed inhibitors that block ENPP1, preserve the immune signal, and function as tumor-specific unmasking agents with favorable pharmacologic properties. Combination therapy and mouse efficacy (Priority: 4/5): The strategy is paired with radiation and checkpoint blockade to amplify immune activation; in mice, it eliminated detectable tumors in multiple aggressive models. Translation to human trials (Priority: 4/5): The discussion covers IND status, dog safety testing, human formulation needs, and the 10-year path from discovery to approved therapy. Personal motivation and future outlook (Priority: 3/5): Li shares that her own breast cancer diagnosis drove her focus on making immunotherapy work for solid tumors and expresses optimism about long remissions and new talent entering the field.

Key Arguments: T cells are the main effectors of anti-cancer immunotherapy, but they need innate immune cells to present tumor signals before they can attack effectively. Solid tumors evade immunotherapy partly because they do not naturally recruit enough T cells and actively suppress immune-detectable danger signals. Cancer cells leak DNA and generate a danger signal that should alert the immune system; ENPP1 degrades that signal and helps tumors stay hidden. Blocking ENPP1 preserves the danger signal, allowing innate immune cells to inform T cells and restore anti-tumor immunity. Metastatic cancers appear to rely even more heavily on ENPP1, making the enzyme an especially attractive drug target. Combining ENPP1 inhibition with radiation or checkpoint inhibitors can produce stronger immune responses and, in mice, complete tumor clearance in several models. The therapeutic concept is designed to be tumor-selective to avoid unwanted autoimmunity against healthy tissues that also release danger signals under stress or aging.

Data Points: Year Stanford podcast launched: 2017 - Russ Altman revisits the original intent of the show. Years since discovery of the cancer danger molecule: About 12 years - Li describes when the cancer-derived signaling mechanism was discovered. Typical number of mutations in cancer cells: About 6 mutations - Used to explain how mutated peptides help the immune system recognize cancer. Time for the therapeutic pathway to human disease: About 10 years - Li states the typical timeline from target validation to a real drug. Clinical trial milestone: IND status obtained - The inhibitor has received FDA authorization to begin human testing. Preclinical species safety testing: Dogs - Li notes safety testing before proceeding toward human trials. Cancer models tested in mice: Metastatic breast cancer, pancreatic cancer, glioblastoma - Aggressive solid tumors used to evaluate the inhibitor strategy. Targeted remission estimate: 10 to 20 years - Li’s estimate of how much remission a successful therapy may add in her lifetime. Late-stage disease outlook: Potential diagnosis in late 60s or 70s - She links environmental factors and delayed cancer onset to future treatment planning.

Pivotal Quotes: "It is an arms race between cancer and our arsenal of immunotherapy. So we have to outsmart cancer." — Lingyin Li: Li’s response in the rapid-fire “Future in a Minute” segment about optimism for the field. "T cells are powerful cancer killers. However, they need innate immune informants." — Lingyin Li: Her summary of the immune system’s division of labor and why tumor unmasking matters. "We have figured out a way to blow cancer's covers." — Russ Altman: Host framing of the episode’s central scientific advance: exposing tumors to immune attack.

Implications: If ENPP1 inhibition translates to humans, it could broaden immunotherapy beyond blood cancers to hard-to-treat solid tumors, especially in combination regimens. The work also suggests a new drug class focused on unmasking tumors rather than directly killing them.